Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (3051)	12/7/2010 11:39:33 AM
From: Jibacoa	Respond to of 3722

ARIA is up for 2nd day on a roll, as it continues its UT.<g> The stock is still up 2.28% with volume above 1M but still below its ADV. bigcharts.marketwatch.com ARIA made a 2Yrs. H today when it traded above its January 2008 H of $4.48 and the next resistance is at the Dec2007 H of $4.87 It announced on Saturday an updated clinical data from a fully enrolled PI of its pan-BCR-ABL inhibitor, ponatinib, in patients with resistant and refractory CML and Ph+ ALL The study demonstrates that in chronic-phase CML patients treated with ponatinib, 66% in the trial achieved a major cytogenetic response, including 100% of patients who also had a T315I mutation. These data were also reported yesterday at the ASH meeting in Orlando. The ACTAY is $6 I will keep a TT at $8 pending the results of the SUCEED trial for radifolimus, which could come before Yr's end.<g> bigcharts.marketwatch.com Bernard